Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbvie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Abbvie

Revenues in the quarter up 26% boosted by Immunology portfolio and Allergan aesthetics portfolio.

By: Contract Pharma

Contract Pharma Staff

Abbvie

2Q Revenues: $10.4 billion (+26%)

2Q Loss: $739 million (earnings were $741 million 2Q19)

YTD Revenues: $14.7 billion (+52%)

YTD Earnings: $2.3 billion (-29%)

Comments: Revenues from the Immunology portfolio were $5.3 billion, up 8%. U.S. Humira sales were nearly $4 billion, up 5%; International Humira sales were $863 million, down 20% due to biosimilar competition. Skyrizi sales were $330 million. Rinvoq revenues were $149 million. Revenues from the Hematologic Oncology portfolio were $1.6 billion, up 26%. Global Imbruvica sales were $1.3 billion, up 17%, with U.S. revenues of $1.1 billion and international profit sharing of $233 million. Global Venclexta sales were $303 million. Revenues from the Aesthetics portfolio were $481 million with Global Botox Cosmetic sales of $226 million. Results reflect acquisition related costs related to the transaction, financing and integration costs of the Allergan acquisition. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters